Dr. Shiyu Wang received her Ph.D. in biochemistry from Penn State University. She has 15+ years of research experience in siRNA and antisense oligonucleotides therapeutic development. Dr. Wang brings in her extensive industrial experience in molecular mechanism of oligonucleotide delivery, disease-causing genes identification, lead optimization, in vitro/in vivo pharmacology and assay development as well as hepatic/extrahepatic platform discovery. During her tenure at the Ionis Pharmaceutical Core Research Department and Dicerna Pharmaceuticals, Dr. Wang spearheaded numerous key preclinical studies using various disease models, led multidisciplinary teams advancing internal and external programs from target identification through late-stage development. Dr. Wang also managed numerous partnering projects including with Eli Lilly, Novo Nordisk, and more.